Compare SMX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMX | LTRN |
|---|---|---|
| Founded | N/A | 2013 |
| Country | Ireland | United States |
| Employees | 19 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 22.2M |
| IPO Year | N/A | 2020 |
| Metric | SMX | LTRN |
|---|---|---|
| Price | $14.20 | $2.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.2M | 222.8K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $1.11 |
| 52 Week High | $490.00 | $5.74 |
| Indicator | SMX | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 71.17 | 46.06 |
| Support Level | $1.10 | $1.96 |
| Resistance Level | $20.09 | $2.41 |
| Average True Range (ATR) | 1.15 | 0.24 |
| MACD | 1.24 | -0.03 |
| Stochastic Oscillator | 59.96 | 17.11 |
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.